Thrombospondin-1 (TSP-1) analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover active pituitary transforming growth factor-β1 (TGF-β1)

Endocrinology

Volumn 153, Issue 8, 2012, Pages 3861-3871

  Recouvreux, M Victoria ^a   Camilletti, M Andrea ^a   Rifkin, Daniel B ^a   Becu Villalobos, Damasia ^b   Díaz Torga, Graciela ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 898; ANGIOGENESIS INHIBITOR; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PROLACTIN; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HYPOPHYSIS; NONHUMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; RAT; TREATMENT DURATION; TUMOR GROWTH;

ANIMALS; DIETHYLSTILBESTROL; FEMALE; OLIGOPEPTIDES; PROLACTINOMA; RATS; RATS, SPRAGUE-DAWLEY; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84864389692     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-1007     Document Type: Article

References (62)

1. Crawford Y, Ferrara N 2009 VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res 335:261-269
2. Folkman J, Shing Y 1992 Angiogenesis. J Biol Chem 267:10931-10934
3. Folkman J, Browder T, Palmblad J 2001 Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost 86:23-33 (Pubitemid 32663933)
4. Arafah BM, Nasrallah MP 2001 Pituitary tumors: pathophysiology, clinical manifestations and management. Endocr Relat Cancer 8:287-305 (Pubitemid 34019376)
5. Melmed S 1999 Pathogenesis of pituitary tumors. Endocrinol Metab Clin North Am 28:1-12, v (Pubitemid 29164776)
6. Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S 2007 Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156:203-216 (Pubitemid 46554515)
7. Pizarro CB, Oliveira MC, Pereira-Lima JF, Leães CG, Kramer CK, Schuch T, Barbosa-Coutinho LM, Ferreira NP 2009 Evaluation of angiogenesis in 77 pituitary adenomas using endoglin as a marker. Neuropathology 29:40-44
8. Schechter J 1972 Ultrastructural changes in the capillary bed of human pituitary tumors. American Journal of Pathology 67:109-126
9. Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL, Wass JA 2000 Angiogenesis in pituitary adenomas and the normal pituitary gland. J Clin Endocrinol Metab 85:1159-1162 (Pubitemid 32269365)
10. Ciccarelli A, Daly AF, Beckers A 2005 The epidemiology of prolactinomas. Pituitary 8:3-6 (Pubitemid 44680079)
11. Vasilev V, Daly AF, Vroonen L, Zacharieva S, Beckers A 2011 Resistant prolactinomas. J Endocrinol Invest 34:312-316
12. Oh MC, Aghi MK 2011 Dopamine agonist-resistant prolactinomas. J Neurosurg 114:1369-1379
13. Gürlek A, Karavitaki N, Ansorge O, Wass JA 2007 What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol 156:143-153 (Pubitemid 46554508)
14. Heaney AP, Fernando M, Melmed S 2002 Functional role of estrogen in pituitary tumor pathogenesis. J Clin Invest 109:277-283 (Pubitemid 34083748)
15. Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S 1999 Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med 5:1317-1321 (Pubitemid 29535612)
16. Sarkar DK 2006 Genesis of prolactinomas: studies using estrogen-treated animals. Front Horm Res 35:32-49 (Pubitemid 44024240)
17. Elias KA, Weiner RI 1984 Direct arterial vascularization of estrogen- induced prolactin-secreting anterior pituitary tumors. Proc Natl Acad Sci USA 81:4549-4553 (Pubitemid 14055929)
18. Elias KA, Weiner RI 1987 Inhibition of estrogen-induced anterior pituitary enlargement and arteriogenesis by bromocriptine in Fischer 344 rats. Endocrinology 120:617-621 (Pubitemid 17020416)
19. Takechi A 1994 Effect of angiogenesis inhibitor TNP-470 on vascular formation in pituitary tumors induced by estrogen in rats. Neurol Med Chir (Tokyo) 34:729-733 (Pubitemid 24367713)
20. Luque GM, Perez-Millán MI, Ornstein AM, Cristina C, Becu-Villalobos D 2011 Inhibitory effects of anti-VEGF strategies in experimental dopamine resistant prolactinomas. J Pharmacol Exp Ther 337:766-774
21. Burris 3rd H, Rocha-Lima C 2008 New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist 13:289-298 (Pubitemid 351679904)
22. Kerbel RS 2008 Tumor angiogenesis. N Engl J Med 358:2039-2049 (Pubitemid 351656458)
23. Haviv F, Bradley MF, Kalvin DM, Schneider AJ, Davidson DJ, Majest SM, McKay LM, Haskell CJ, Bell RL, Nguyen B, Marsh KC, Surber BW, Uchic JT, Ferrero J, Wang YC, Leal J, Record RD, Hodde J, Badylak SF, Lesniewski RR, Henkin J 2005 Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. J Med Chem 48:2838-2846 (Pubitemid 40548098)
24. Lawler J 2002 Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 6:1-12 (Pubitemid 44133979)
25. Anderson JC, Grammer JR, Wang W, Nabors LB, Henkin J, Stewart Jr JE, Gladson CL 2007 ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis. Cancer Biol Ther 6:454-462 (Pubitemid 47328316)
26. Yang Q, Tian Y, Liu S, Zeine R, Chlenski A, Salwen HR, Henkin J, Cohn SL 2007 Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Cancer Res 67:1716-1724 (Pubitemid 46383398)
27. Garside SA, Henkin J, Morris KD, Norvell SM, Thomas FH, Fraser HM 2010 A thrombospondin-mimetic peptide, ABT-898, suppresses angiogenesis and promotes follicular atresia in pre- and early- antral follicles in vivo. Endocrinology 151:5905-5915
28. Burns G, Sarkar DK 1993 Transforming growth factor-β1-like immunoreactivity in the pituitary gland of the rat: effect of estrogen. Endocrinology 133:1444-1449 (Pubitemid 23267804)
29. Sarkar AJ, Chaturvedi K, Chen CP, Sarkar DK 2007 Changes in thrombospondin-1 levels in the endothelial cells of the anterior pituitary during estrogen-induced prolactin-secreting pituitary tumors. J Endocrinol 192:395-403 (Pubitemid 46444441)
30. Schultz-Cherry S, Ribeiro S, Gentry L, Murphy-Ullrich JE 1994 Thrombospondin binds and activates the small and large forms of latent transforming growth factor-β in a chemically defined system. J Biol Chem 269:26775-26782 (Pubitemid 24332871)
31. Rifkin DB 2005 Latent transforming growth factor-β (TGF-β) binding proteins: orchestrators of TGF-β availability. J Biol Chem 280: 7409-7412 (Pubitemid 40349631)
32. Mehra A, Wrana JL 2002 TGF-β and the Smad signal transduction pathway. Biochem Cell Biol 80:605-622 (Pubitemid 36124821)
33. Sarkar DK, Kim KH, Minami S 1992 Transforming growth factor-β1 messenger RNA and protein expression in the pituitary gland: its action on prolactin secretion and lactotropic growth. Mol Endocrinol 6:1825-1833
34. De A, Morgan TE, Speth RC, Boyadjieva N, Sarkar DK 1995 Pituitary lactotrope expresses transforming growth factor β (TGF-β) type II receptor mRNA and protein and contains I-TGF-β1 binding sites. J Endocrinol 149:19-27
35. Pastorcic M, De A, Boyadjieva N, Vale W, Sarkar DK 1995 Reduction in the expression and action of transforming growth factor-β1 on lactotropes during estrogen-induced tumorigenesis. Cancer Res 55:4892-4898
36. Recouvreux MV, Guida MC, Rifkin DB, Becu-Villalobos D, Díaz-Torga G 2011 Active and total transforming growth factor-β1 are differentially regulated by dopamine and estradiol in the pituitary. Endocrinology 152:2722-2730
37. Guo NH, Krutzsch HC, Inman JK, Shannon CS, Roberts DD 1997 Antiproliferative and antitumor activities of D-reverse peptides derived from the second type-1 repeat of thrombospondin-1. J Pept Res 50:210-221 (Pubitemid 27381450)
38. Ebbinghaus S, Hussain M, Tannir N, Gordon M, Desai AA, Knight RA, Humerickhouse RA, Qian J, Gordon GB, Figlin R 2007 Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin Cancer Res 13:6689-6695 (Pubitemid 350206805)
39. Markovic SN, Suman VJ, Rao RA, Ingle JN, Kaur JS, Erickson LA, Pitot HC, Croghan GA, McWilliams RR, Merchan J, Kottschade LA, Nevala WK, Uhl CB, Allred J, Creagan ET 2007 A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol 30:303-309 (Pubitemid 46884153)
40. Gordon MS, Mendelson D, Carr R, Knight RA, Humerickhouse RA, Iannone M, Stopeck AT 2008 A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer. Cancer 113:3420-3429
41. Nabors LB, Fiveash JB, Markert JM, Kekan MS, Gillespie GY, Huang Z, Johnson MJ, Meleth S, Kuo H, Gladson CL, Fathallah-Shaykh HM 2010 A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Arch Neurol 67:313-319
42. Campbell N, Greenaway J, Henkin J, Petrik J 2011 ABT-898 induces tumor regression and prolongs survival in a mouse model of epithelial ovarian cancer. Mol Cancer Ther 10:1876-1885
43. Hasan J, Byers R, Jayson GC 2002 Intra-tumoural microvessel density in human solid tumours. Br J Cancer 86:1566-1577 (Pubitemid 34628110)
44. Lloyd RV, Scheithauer BW, Kuroki T, Vidal S, Kovacs K, Stefaneanu L 1999 Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr Pathol 10:229-235
45. McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA, Gittoes NJ 2002 Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87:4238-4244
46. Cristina C, Díaz-Torga G, Baldi A, Góngora A, Rubinstein M, Low MJ, Becú-Villalobos D 2005 Increased pituitary vascular endothelial growth factor-A in dopaminergic D2 receptor knockout female mice. Endocrinology 146:2952-2962 (Pubitemid 41002802)
47. Cristina C, Tornadú IG, Millán MIP, Díaz-Torga G, Becu-Villalobos D 2006 Factores de crecimiento y antiangiogenesis en prolactinomas resistentes a dopamina. Anales de la Academia Nacional de Ciencias (Buenos Aires) 39:1-15
48. Mallea-Gil MS, Cristina C, Perez-Millan MI, Villafañe AM, Ballarino C, Stalldecker G, Becu-Villalobos D 2009 Invasive giant prolactinoma with loss of therapeutic response to cabergoline: expression of angiogenic markers. Endocr Pathol 20:35-50
49. Cristina C, Perez-Millan MI, Luque G, Dulce RA, Sevlever G, Berner SI, Becu-Villalobos D 2010 VEGF and CD31 association in pituitary adenomas. Endocr Pathol 21:154-160
50. Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL, Wass JA 2000 Angiogenesis in pituitary adenomas - relationship to endocrine function, treatment and outcome. J Endocrinol 165:475-481 (Pubitemid 30341096)
51. Febbraio M, Hajjar DP, Silverstein RL 2001 CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 108:785-791 (Pubitemid 32880285)
52. Rice C, Huang LE 2010 From antiangiogenesis to hypoxia: current research and future directions. Cancer Manag Res 3:9-16
53. Campbell NE, Greenaway J, Henkin J, Moorehead RA, Petrik J 2010 The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer. Neoplasia 12:275-283
54. Sarkar DK, Pastorcic M, De A, Engel M, Moses H, Ghasemzadeh MB 1998 Role of transforming growth factor-β type I and TGF-βtype II receptors in the TGF-β1 regulated gene expression in pituitary prolactin-secreting lactotropes. Endocrinology 139:3620-3628 (Pubitemid 28512322)
55. Yoshinaga K, Obata H, Jurukovski V, Mazzieri R, Chen Y, Zilberberg L, Huso D, Melamed J, Prijatelj P, Todorovic V, Dabovic B, Rifkin DB 2008 Perturbation of transforming growth factor (TGF)-β1 association with latent TGF-β binding protein yields inflammation and tumors. Proc Natl Acad Sci USA 105:18758-18763
56. Silverstein RL, Febbraio M 2009 CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal 2:re3
57. Young GD, Murphy-Ullrich JE 2004 The tryptophan-rich motifs of the thrombospondin type 1 repeats bind VLAL motifs in the latent transforming growth factor-β complex. J Biol Chem 279:47633-47642 (Pubitemid 39540909)
58. Miyazono K, Heldin CH 1991 Latent forms of TGF-β: molecular structure and mechanisms of activation. Ciba Found Symp 157:81-89; discussion 89-92
59. Taipale J, Miyazono K, Heldin CH, Keski-Oja J 1994 Latent transforming growth factor-β1 associates to fibroblast extracellular matrix via latent TGF-β binding protein. J Cell Biol 124:171-181 (Pubitemid 24054619)
60. Taipale J, Saharinen J, Hedman K, Keski-Oja J 1996 Latent transforming growth factor-β1 and its binding protein are components of extracellular matrix microfibrils. J Histochem Cytochem 44:875-889 (Pubitemid 26266744)
61. Koski C, Saharinen J, Keski-Oja J 1999 Independent promoters regulate the expression of two amino terminally distinct forms of latent transforming growth factor-β binding protein-1 (LTBP-1) in a cell type-specific manner. J Biol Chem 274:32619-32630 (Pubitemid 129535288)
62. Weikkolainen K, Keski-Oja J, Koli K 2003 Expression of latent TGF-β binding protein LTBP-1 is hormonally regulated in normal and transformed human lung fibroblasts. Growth Factors 21:51-60 (Pubitemid 37369348)